IBD Patients: Consider Giving Infliximab a Second Try
Restarting infliximab therapy after a drug holiday is safe and effective for patients with inflammatory bowel disease (IBD), according to a new study in Clinical Gastroenterology and Hepatology.
Patients who were in remission at the time infliximab was discontinued were the best candidates, with a 78 percent response rate at one year.
Drug Shows Promise for Subset of Stage III Colon Cancer Patients
A subset of patients with stage III colon cancer had improved survival rates when treated with irinotecan-based therapy, according to a new study in Gastroenterology.
AGA Institute Journal Embargo Policy
When a manuscript is accepted for publication in either Gastroenterology or Clinical Gastroenterology and Hepatology, it is under embargo and not for public release until publication. Articles are typically embargoed until 3 p.m. ET the day of online publication.
Authors are permitted to present their research prior to publication before peers at scientific meetings, but should refrain from distributing copies of their paper, including data tables and figures.
AGA News Release Archives
Patient Education Materials
To help you understand and manage your digestive health condition or to prepare for your procedure, the AGA Institute provides patients with educational information, designed to give you some basic facts and to serve as a starting point for discussions with your doctor.
AGA Expert Blog Posts
AGA experts are blogging about new research and hot topics in gastroenterology. View the most recent posts.
AGA Senior Director of Public Relations